Will David Sinclair be regularly taking a SGLT2 inhibitor (canagliflozin, empagliflozin) by the end of 2025?
3
Ṁ140Ṁ591resolved Jan 2
Resolved
NO1H
6H
1D
1W
1M
ALL
This question is managed and resolved by Manifold.
Market context
Get 
1,000 to start trading!
1,000🏅 Top traders
| # | Trader | Total profit |
|---|---|---|
| 1 | Ṁ112 | |
| 2 | Ṁ9 |
Sort by:
@creator @mods Could you please resolve?
https://novoslabs.com/best-anti-aging-supplements-that-harvard-scientist-david-sinclair-takes/
People are also trading
Related questions
Will Mike Lustgarten start to regularly ANY of {rapamycin, metformin, acarbose, SGLT2 inhibitors) by the end of 2027?
58% chance
Will Morgan Levine start to regularly ANY of {rapamycin, metformin, acarbose, SGLT2 inhibitors) by the end of 2027?
54% chance
Will a majority government owned company introduce a new GLP-1 drug before 2040?
15% chance
Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?
30% chance
Will Matt Kaeberlein start taking semaglutide/ozempic by 2030?
41% chance
Will a GLP-1 receptor agonist (Ozempic-like drug) be added to public water supplies in the United States by 2075?
10% chance
Will ANY of {metformin, canagliflozin, acarbose, rapamycin} be made OTC to purchase in US by Jan2028?
48% chance
By 2029, will there be an FDA approval of GLP-1 for a substance use disorder?
86% chance
Will 10 million Americans be on semaglutide (or yet-to-be-approved equally good or superior alternatives) by the end of 2030?
78% chance
What fraction of US adults will regularly take GLP-1 drugs in 2030?